Literature DB >> 2117206

Early versus late surfactant replacement therapy in severe respiratory distress syndrome.

C P Speer1, K Harms, E Herting, N Neumann, T Curstedt, B Robertson.   

Abstract

26 preterm infants with severe respiratory distress syndrome (RDS) have been treated at different ages with a single dose of natural porcine surfactant (Curosurf, 200 mg/kg). Criteria for treatment included clinical and radiological signs of severe RDS (grade III-IV), requirement of artificial ventilation and an FiO2 greater than or equal to 0.6. Nineteen neonates have been subjected to early treatment (2-15 h of age, mean birth weight SD: 1201 +/- 387 g) and 7 patients to late treatment (greater than 15 h to 48 h of age, birth weight SD 1624 +/- 649 g). Average FiO2 before treatment was 0.88 in early-treated patients and 0.8 in late-treated patients, age at treatment was 4.6 h and 36 h, respectively (median). Both early- and late-treated infants exhibited an improvement in oxygenation (more than twofold increase of the PaO2/FiO2 ratio) within 5 minutes after initiation of therapy. Average duration of intermittent pressure ventilation was 15 days in the early treatment group and 19 days in the late treatment group. Total exposition to greater than 21% oxygen was 21 days in early-treated and 48 days in late-treated infants. Pneumothorax occurred in none of the patients. All early treated infants survived without signs of severe bronchopulmonary dysplasia (BPD greater than 21% O2, greater than 90 days plus radiological changes). However, two out of seven late-treated infants developed severe BPD; one patient died as a consequence of cardiopulmonary deterioration. Two patients in the early treatment group died of nonpulmonary complications. We conclude that surfactant replacement therapy should probably be initiated as soon as possible after manifestation of severe RDS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117206     DOI: 10.1007/bf02718222

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  11 in total

1.  Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Collaborative European Multicenter Study Group.

Authors: 
Journal:  Pediatrics       Date:  1988-11       Impact factor: 7.124

2.  Surfactant replacement therapy at birth: final analysis of a clinical trial and comparisons with similar trials.

Authors:  J W Kendig; R H Notter; C Cox; J L Aschner; S Benn; R M Bernstein; K Hendricks-Munoz; W M Maniscalco; L A Metlay; D L Phelps
Journal:  Pediatrics       Date:  1988-11       Impact factor: 7.124

3.  Radiographic features of pulmonary oxygen toxicity in the newborn: Bronchopulmonary dysplasia.

Authors:  W H Northway; R C Rosan
Journal:  Radiology       Date:  1968-07       Impact factor: 11.105

4.  Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease.

Authors:  J D Gitlin; R F Soll; R B Parad; J D Horbar; H A Feldman; J F Lucey; H W Taeusch
Journal:  Pediatrics       Date:  1987-01       Impact factor: 7.124

5.  Double-blind controlled trial of single-dose treatment with bovine surfactant in severe hyaline membrane disease.

Authors:  T N Raju; D Vidyasagar; R Bhat; D Sobel; K M McCulloch; M Anderson; H Maeta; P S Levy; S Furner
Journal:  Lancet       Date:  1987-03-21       Impact factor: 79.321

6.  Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial.

Authors:  G Enhorning; A Shennan; F Possmayer; M Dunn; C P Chen; J Milligan
Journal:  Pediatrics       Date:  1985-08       Impact factor: 7.124

7.  Prophylactic treatment of very premature infants with human surfactant.

Authors:  T A Merritt; M Hallman; B T Bloom; C Berry; K Benirschke; D Sahn; T Key; D Edwards; A L Jarvenpaa; M Pohjavuori
Journal:  N Engl J Med       Date:  1986-09-25       Impact factor: 91.245

8.  Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants.

Authors:  M S Kwong; E A Egan; R H Notter; D L Shapiro
Journal:  Pediatrics       Date:  1985-10       Impact factor: 7.124

9.  [Treatment of severe respiratory distress syndrome in the premature infant with natural surfactant].

Authors:  C P Speer; K Harms; U Müller; W Schröter; T Curstedt; B Robertson
Journal:  Monatsschr Kinderheilkd       Date:  1988-02       Impact factor: 0.323

10.  Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial.

Authors:  M Hallman; T A Merritt; A L Jarvenpaa; B Boynton; F Mannino; L Gluck; T Moore; D Edwards
Journal:  J Pediatr       Date:  1985-06       Impact factor: 4.406

View more
  4 in total

Review 1.  Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome.

Authors:  K L Dechant; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 2.  Surfactant replacement therapy.

Authors:  M J Kresch; W H Lin; R S Thrall
Journal:  Thorax       Date:  1996-11       Impact factor: 9.139

Review 3.  Future developments in the pharmacotherapy of lung disease.

Authors:  A Van der Kuy
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 4.  The surfactant system of the adult lung: physiology and clinical perspectives.

Authors:  H Hamm; H Fabel; W Bartsch
Journal:  Clin Investig       Date:  1992-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.